SCHEMBL12464834

SCHEMBL12464834

CCCc1c[nH]c2ccc(Cl)cc12

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 4/20 0.71
TRPM8 Q7Z2W7 1/20 0.71
GPR84 Q9NQS5 1/20 0.69
SLC6A4 P31645 4/20 0.66
TSHR P16473 1/20 0.64
MTNR1A P48039 1/20 0.61
MTNR1B P49286 1/20 0.61
GFER P55789 1/20 0.58
HSD17B10 Q99714 1/20 0.58
HTR1A P08908 2/20 0.57
HTR1D P28221 2/20 0.57
HTR1B P28222 2/20 0.57
ADRA2A P08913 1/20 0.57
DRD2 P14416 1/20 0.57
ADRA2B P18089 1/20 0.57
ADRA2C P18825 1/20 0.57
SLC6A2 P23975 1/20 0.57
ADRA1D P25100 1/20 0.57
HTR2C P28335 1/20 0.57
HTR1E P28566 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28117188 0.90 SLC6A4 (0.71) HTR2ATRPM8GPR84SLC6A4TSHR
SCHEMBL7466733 0.89 SLC6A4 (0.69) HTR2ATRPM8GPR84SLC6A4TSHR
SCHEMBL3181757 0.86 GPR84 (0.69) HTR2ATRPM8GPR84SLC6A4TSHR
SCHEMBL10119751 0.86 GPR84 (0.73) HTR2ATRPM8GPR84SLC6A4TSHR
SCHEMBL11162502 0.83 HTR2A (0.71) HTR2ATRPM8GPR84SLC6A4TSHR
SCHEMBL626030 0.83 HTR2A (1.00) HTR2ATRPM8GPR84SLC6A4TSHR
SCHEMBL30724496 0.83 HTR2A (1.00) HTR2ATRPM8GPR84SLC6A4TSHR
SCHEMBL7718374 0.83 HTR2A (0.71) HTR2ATRPM8GPR84SLC6A4TSHR
SCHEMBL28837438 0.83 HTR2A (0.71) HTR2ATRPM8GPR84SLC6A4TSHR
SCHEMBL24243766 0.82 HTR2A (0.72) HTR2ATRPM8GPR84SLC6A4HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4452986-A1 SEROTONIN RECEPTOR AGONISTS AND METHODS OF MAKING AND USING THE SAME Kuleon LLC (US) 2024-10-30 EP disclosed
WO-2023225043-A1 TRICYCLIC AND TETRACYCLIC SEROTONIN RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME KULEON LLC (US) 2023-11-23 WO disclosed
WO-2023122135-A1 SEROTONIN RECEPTOR AGONISTS AND METHODS OF MAKING AND USING THE SAME KULEON LLC (US) 2023-06-29 WO disclosed
WO-2023023298-A1 HALLUCINOGENIC AND NON-HALLUCINOGENIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME PSILOSTERICS, LLC (US) 2023-02-23 WO disclosed
CN-104163813-B Substituted indole compound, and preparation method and use thereof 广东东阳光药业有限公司 2017-02-01 CN disclosed
US-20110184171-A1 ACYLATION OF HINDERED AMINES AND FUNCTIONALIZED BIS-PEPTIDES OBTAINED THEREBY TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2011-07-28 US disclosed
US-20110046160-A1 Novel Class of Spiro Piperidines for the Treatment of Neurodegenerative Diseases PFIZER, INC. 2011-02-24 US disclosed
EP-1465880-B1 5-SULPHANYL-4H-1,2,4-TRIAZOLE DERIVATIVES AND THEIR USE TO TREAT DISORDERS ASSOCIATED WITH SOMATOSTATINE IPSEN PHARMA (FR) 2009-08-05 EP disclosed
CN-1391556-A novel IL-8 receptor antagonists FOURNIER IND & SANTE (FR) 2003-01-15 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110184171-A1 ACYLATION OF HINDERED AMINES AND FUNCTIONALIZED BIS-PEPTIDES OBTAINED THEREBY DNPEP, PTMS, NAAA HTR2A 4023/4885TRPM8 3961/4885GPR84 2663/4885
US-20110046160-A1 Novel Class of Spiro Piperidines for the Treatment of Neurodegenerative Diseases SNCA, PARK7, HTT HTR2A 182/4885TRPM8 1235/4885GPR84 2307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.